The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines
August 2, 2007
By:
Jee Loon Look
,
Barbara Butler
,
Mohammad Al-Khalili
,
Yin-Hwa Lai
,
Vladimir Frolov
,
Chen Xue Zhang
,
Jianxin Yang
,
Danielle Smyla
,
Armond Mayo
,
Jianmei Yu
,
Mimi Guebre-Xabier
,
Sarah Frech
,
Larry Ellingsworth
,
Robert Seid
,
Gregory Glenn
In animal studies, we have demonstrated that the dose of an injected H5N1 vaccine candidate can be significantly reduced by using a skin patch containing E. coli heat-labile enterotoxin (LT) applied over the injection site. LT-activated epidermal Langerhans cells migrate to the nearby draining lymph node and enhance the immune response to the injected antigen. A dry patch formulation has been optimized as a dose sparing strategy for pandemic flu and other vaccines. Iomai Corporation has developed a proprietary stabilizing formulation for the patch that allows use and storage at ambient temperature. The patch withstands temperature extremes during shipment, and is suitable for stockpiling.
|
